Comparative Pharmacology
Head-to-head clinical analysis: DAYTRANA versus DYANAVEL XR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYTRANA versus DYANAVEL XR 10.
DAYTRANA vs DYANAVEL XR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their extracellular concentrations.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
Initial: 10 mg transdermal patch applied to hip for 9 hours daily; may titrate weekly in increments of 5 mg to a maximum of 30 mg/day.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
None Documented
None Documented
Terminal half-life in children is approximately 5–6 hours; in adults, approximately 5 hours; wears off within 12 hours of patch removal.
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
Renal (approx. 78% unchanged) and fecal (approx. 10%); remainder as metabolites.
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Category C
Category C
CNS Stimulant
CNS Stimulant